[AGIO] Agios Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 43.15 Change: 1.78 (4.3%)
Ext. hours: Change: 0 (0%)

chart AGIO

Refresh chart

Strongest Trends Summary For AGIO

AGIO is in the long-term down -58% below S&P in 6 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and inborn errors of metabolism (IEMs) in the United States. Its product candidates include AG-221, an oral inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations, as well as for the Type II D-2 hydroxyglutaric aciduria treatment; and AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations. The company is also developing AG-348, an oral small molecule activator of PKR enzyme for the treatment of patients with pyruvate kinase deficiency. It has a collaboration agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology. Agios Pharmaceuticals, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Fundamental Ratios
Shares Outstanding EPS-6 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 306.63% Sales Growth - Q/Q133.68% P/E-8.63
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-9.74% ROE-10.83% ROI
Current Ratio10.01 Quick Ratio Long Term Debt/Equity Debt Ratio0.09
Gross Margin Operating Margin-51.61% Net Profit Margin-50.7% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities1.82 M Cash From Investing Activities44.99 M Cash From Operating Activities-25.59 M Gross Profit
Net Profit-4.96 M Operating Profit-5.2 M Total Assets474.34 M Total Current Assets364.14 M
Total Current Liabilities36.38 M Total Debt Total Liabilities47.52 M Total Revenue34.2 M
Technical Data
High 52 week75.11 Low 52 week42.73 Last close62.35 Last change5.93%
RSI68.62 Average true range2.74 Beta1.94 Volume828.59 K
Simple moving average 20 days13.04% Simple moving average 50 days18.89% Simple moving average 200 days3.15%
Performance Data
Performance Week5.16% Performance Month20.07% Performance Quart-5.23% Performance Half4.56%
Performance Year26.83% Performance Year-to-date35.22% Volatility daily2.87% Volatility weekly6.41%
Volatility monthly13.13% Volatility yearly45.49% Relative Volume130.51% Average Volume563.62 K
New High New Low

News

2019-03-16 09:30:01 | Why Is Agios Pharmaceuticals AGIO Up 13.2% Since Last Earnings Report?

2019-03-06 14:01:46 | All You Need To Know About Agios Pharmaceuticals, Inc.’s NASDAQ:AGIO Financial Health

2019-03-04 07:00:00 | Agios to Present at the Cowen 39th Annual Health Care Conference on Monday, March 11, 2019

2019-02-25 07:00:00 | Agios Reports Updated Data from Phase 1 Study of Ivosidenib in Combination with Azacitidine Demonstrating Deep and Durable Responses in Newly Diagnosed IDH1 Mutant Acute Myeloid Leukemia AML Patients

2019-02-22 07:25:00 | Analysis: Positioning to Benefit within Quest Diagnostics, Autodesk, Agios Pharmaceuticals, AMN Healthcare Services, Vistra Energy, and Helen of Troy — Research Highlights Growth, Revenue, and Consolidated Results

2019-02-21 09:34:02 | Agios' Tibsovo Gets FDA Priority Review in First-Line Cancer

2019-02-21 07:00:00 | Agios to Present at the Leerink Global Healthcare Conference on Thursday, February 28, 2019

2019-02-20 15:43:40 | Edited Transcript of AGIO earnings conference call or presentation 14-Feb-19 1:00pm GMT

2019-02-20 07:00:00 | Agios Announces FDA Acceptance of Supplemental New Drug Application for TIBSOVO® ivosidenib for the Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation Not Eligible for Standard Therapy

2019-02-15 14:25:07 | Agios AGIO Q4 Earnings Beat, Tibsovo Sales Push Up Stock

2019-02-14 12:01:58 | Agios Pharmaceuticals Inc AGIO Q4 2018 Earnings Conference Call Transcript

2019-02-14 09:10:02 | Agios Pharmaceuticals AGIO Reports Q4 Loss, Tops Revenue Estimates

2019-02-14 08:10:46 | Agios Pharmaceuticals: 4Q Earnings Snapshot

2019-02-14 07:00:00 | Agios Reports Fourth Quarter and Full Year 2018 Financial Results

2019-02-11 12:09:14 | Agios ex-CEO joins GV as life sciences investment team's co-head

2019-02-08 08:04:12 | See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.

2019-02-07 10:31:03 | Agios Pharmaceuticals AGIO May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

2019-01-29 13:52:34 | Have Insiders Been Selling Agios Pharmaceuticals, Inc. NASDAQ:AGIO Shares?

2019-01-29 08:05:17 | See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.

2019-01-22 08:04:06 | See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.

2019-01-10 12:07:29 | 5 Biotech Stocks That Could Face M&A Next!

2019-01-09 08:05:49 | See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.

2019-01-07 07:00:00 | Agios Highlights Key 2019 Initiatives to Broaden Potential for Cancer and Rare Genetic Disease Programs to Build Long-Term Value

2018-12-28 07:00:00 | Agios to Present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019

2018-12-14 12:03:39 | Our Take On Agios Pharmaceuticals, Inc.’s NASDAQ:AGIO CEO Salary

2018-12-13 07:20:00 | Market Trends Toward New Normal in DXC Technology, Patterson Companies, Lumentum, DSW, Agios Pharmaceuticals, and Six Flags Entertainment Corporation New — Emerging Consolidated Expectations, Analyst Ratings

2018-12-13 03:20:00 | Hedge Funds Are Selling Agios Pharmaceuticals Inc AGIO

2018-12-12 07:00:00 | Today's Research Reports on Trending Tickers: Arrowhead Pharmaceuticals and Agios Pharmaceuticals

2018-12-08 17:36:00 | Could These Be the Next 2 Biotech Buyouts?

2018-12-07 07:00:00 | Today's Research Reports on Trending Tickers: Amarin Corporation and Agios Pharmaceuticals

2018-12-03 10:30:00 | Agios Presents Updated Data from the Ivosidenib Phase 1 Dose-Escalation and Expansion Trial in IDH1 Mutant Positive Patients with Newly Diagnosed Acute Myeloid Leukemia AML Ineligible for Standard Treatment and Myelodysplastic Syndrome MDS

2018-12-03 10:15:00 | Agios Announces Updated Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Standard Induction and Consolidation Chemotherapy in Newly Diagnosed AML Patients With an IDH Mutation

2018-11-26 07:05:00 | Today's Research Reports on Trending Tickers: Agios Pharmaceuticals and Amarin Corporation

2018-11-16 07:00:00 | Agios Presents Updated Data from Phase 1 Dose-Escalation Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma

2018-11-14 06:55:00 | Today's Research Reports on Trending Tickers: Exelixis and Agios Pharmaceuticals

2018-11-08 08:00:00 | New Research Coverage Highlights John B. Sanfilippo & Son, Axcelis Technologies, Cogent Communications, Star Bulk Carriers, Agios Pharmaceuticals, and MDC Partners — Consolidated Revenues, Company Growth, and Expectations for 2018

2018-11-08 06:00:00 | 3 Biotech Stocks Poised for Big Rebounds

2018-11-02 13:01:05 | Agios AGIO Q3 Earnings Beat, Tibsovo Sales Drive Stock

2018-11-01 14:15:36 | Edited Transcript of AGIO earnings conference call or presentation 1-Nov-18 12:00pm GMT

2018-11-01 10:41:02 | Agios Pharmaceuticals AGIO Reports Q3 Loss, Tops Revenue Estimates

2018-11-01 09:20:05 | Agios to Present Updated Clinical Data at the 2018 ASH Annual Meeting

2018-11-01 08:22:23 | Agios Pharmaceuticals: 3Q Earnings Snapshot

2018-11-01 08:00:00 | Today's Research Reports on Trending Tickers: Agios Pharmaceuticals and Incyte

2018-11-01 07:00:00 | Agios Reports Third Quarter 2018 Financial Results

2018-10-26 08:05:31 | See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.

2018-10-19 11:44:03 | Agios Rides on Tibsovo Approval Amid Reliance on Celgene

2018-10-18 07:00:00 | Agios to Webcast Conference Call of Third Quarter 2018 Financial Results on November 1, 2018

2018-10-11 08:06:17 | See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.

2018-10-06 08:06:16 | See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.

2018-10-05 08:06:28 | See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.